Practitioner's Docket No. FINKEL-1 CONT II

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sydney D. Finkelstein, Patricia Anne Finkelstein

BA05 Acation No.: 10/008,278 Filed: November 5, 2001

Group No.: 1634 Examiner: J. Goldberg

For: TOPOGRAPHIC GENOTYPING

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

TIME OF TRANSMITTAL OF ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

- The information disclosure statement transmitted herewith is being filed after three months of the 1. filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311

whichever occurs first.

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

		MAILING
	deposited with the United States Postal Service in an envel 313-1450.	ope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA
	37 C.F.R. § 1.8(a)	37 C.F.R. § 1.10*
Χv	with sufficient postage as first class mail.	☐ as "Express Mail Post Office to Addressee"
		Mailing Label No (mandatory)
١٥	facsimile transmitted to the Patent and Trademark Office,	TRANSMISSION (703) L. Muka
Da	te: 7/3/03	Signature
07/09/2003 TRES	HAH1 00000030 10008278	Tracey L. Milka
ALLAND IBED	MUNIT ANANANA IAAARIA	(type or print name of person certifying)
01 FC:1806	180.00 GP	(At t

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

FEE

2. Accompanying this transmittal is the fee for submission of an information disclosure statement under section 1.97(c). (\$180.00)

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$180.00

METHOD OF PAYMENT OF FEE

4. Attached is a check in the amount of \$180.00.

A duplicate of this paper is attached.

Ansel M. Schwartz Registration No. 30,587 Attorney at Law 201 N. Craig Street Suite 304

Pittsburgh, PA 15213 412-621-9222

PTO/SB/08b(05-03) Approved for use through 04/30/2003, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet

Substitute for for 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/008,278				
Filing Date	11/05/2001				
First Named Inventor	Sydney D. Finkelstein				
Art Unit	1634				
Examiner Name	J. Goldberg				
Attorney Docket Number	FINKEL-1 CONTII				

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials* Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (b magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, ci and/or country where published.						
		FINKELSTEIN SD, ET AL., "'Kras-2 topographic genotyping of pancreatic adenocarcinoma.'," Arch. Surg., Vol. 129 (No. 4), p. 367-372, (April 1, 1994). FINKELSTEIN SD, ET AL., "'Genotypic classification of colorectal adenocarconoma. Biologic				
		behavior correlates with K-ras-2 mutation type.'," Cancer (1993), Vol. 71 (No. 12), p. 3827-3838, (June 15, 1993).				
		REINCKE M. ET AL., ""p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies.'," J. Clin Endocrin. and Metabol. (1994), Vol. 78 (No. 3), p. 790-794, (March 1, 1994).				
		SLEBOS, RJC, ET AL., "K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.'," New Engl. J. Med. (1990), Vol. 323 (No. 9), p. 561-565, (August 3, 1990).				

Examiner		Date	ì	
Signature	_	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (05-03)

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Und	er the Parerwork Reduction Act of 1995	, no pe	rsons are required to re		tion unless it contains a valid OMB control number.		
Substitute for form 1449A/PTO				Complete if Known			
				Application Number	10/008,278		
ll	NFORMATION DISC	CLC	SURE	Filing Date	11/05/2001		
S	STATEMENT BY AF	PL	ICANT	First Named Inventor	Sydney D. Finkelstein		
(Use as many sheets as necessary)				Art Unit	1634		
				Examiner Name	J. Goldberg		
Sheet	11	of	11	Attorney Docket Number	FINKEL-1 CONTIL		

			U. S. PATENT D		
Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	NO.	200	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (if known)}			rigules Appear
		US-			
		US-			
		US-			
		US-	·		
		US-	 		
		US-			
		U\$-			· · · · · · · · · · · · · · · · · · ·
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
	See	Attachmen 1						

Examiner		Date	
Signature		Considered	
•	·		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.